JN JNJ Johnson & Johnson Loading... : Bullish and Bearish Analyst Opinions

J&J undervalued with no patent cliffs.

Author argues novel MOA drugs like Obe are safer than established JAK inhibitors based on long-term data, favoring Obe over Rinvoq for safety-conscious patients.

JNJ beginning new growth cycle.

JNJ is safe for children.

J&J is a safe haven stock.

Adam May questions whether JNJ's IP situation and high trial costs justify a large study for their UC drugs nearing loss of exclusivity.

The tweet reports a shift in UK retail investor preferences from defensive stocks in the 2010s to growth names like TSLA and NVDA, attributing the change to social media influence without expressing a forward-looking opinion.

Adam May argues AbbVie's extended half-life bispecific antibody for IL23 and TL1A will crush Syros' costly separate-drug combo strategy, making Syros' clinical and financial path far more difficult.

JNJ is a buy, great balance sheet.

J&J triple-A balance cheap pipeline.

J&J best pipeline at discount.

Favor defensive secular growth in staples and healthcare.

Buy J&J on weakness for long-term.

J&J CFO bullish on stock due to growth.

Johnson & Johnson transformed with strong pipeline.

Cramer stated the FDA approval for JNJ's oral psoriasis pill, icotidib, is "terrific news" that was ignored due to a bad market day. He believes it could "eat [AbbVie's Skyrizi] alive" in a large market and calls the stock's pullback a "great buying opportunity." The oral formulation is preferred over injectables, giving JNJ a potential edge. The drug also has a pipeline for other indications, with peak sales estimates ranging from $5B to $7.5B. The positive development is company-specific and significant, but the stock price did not react due to macro noise (oil prices), creating a mispricing. Pricing and market uptake challenges against entrenched competitors; broader market decline persists.

Go long J&J as its new psoriasis drug is expected to successfully compete with and take market share from a major incumbent drug from AbbVie.

"The Trump RX plan of course is developed by these private meetings with the pharma types... especially Merc and Eli Lily and J&J have been very effective at that." Companies that engage Trump privately and collectively can shape policy in their favor without triggering his public attacks. The pharmaceutical sector successfully used this playbook to navigate drug pricing policies, resulting in a plan that was much better for the industry than critics anticipated. LONG. These large pharma companies have proven they can manage political and regulatory risk under Trump by using private, collective influence to protect their margins. The presence of RFK Jr. in the administration is noted as a "pernicious problem" that could introduce unpredictable regulatory or narrative risks for the sector.

The FDA's clearance of a new combo drug, backed by strong survival data, is a positive fundamental catalyst for future revenue.

Johnson & Johnson (JNJ) is identified as a "Wide Moat" company that passed the author's fundamental screens and is also explicitly listed as "Undervalued." As a high-quality, defensive company with a strong moat trading at what the author considers an undervalued price, JNJ fits the core criteria of the investment framework for a long-term holding. JNJ is a prime candidate for inclusion in the author's portfolio, subject to a final qualitative review and a technically opportune entry point. Ongoing litigation risks (e.g., talc lawsuits) could create headline risk and financial liabilities. The pharmaceutical pipeline's success is uncertain and crucial for future growth.

Cramer notes that February "demolished software" and "minimized hardware" but the winners were "prosaic companies with popular brands" and "earthmovers." In a month of indecision, inflation, and rate fears, capital is fleeing high-beta tech and hiding in tangible, defensive value stocks and industrials. LONG. These are the current safe havens in a volatile market. A sudden return to "risk-on" sentiment could see these lag behind tech.

February winners were "prosaic companies" with popular brands and earth movers. In a month where software and hardware were demolished, capital hid in these defensive names. This trend is the current market regime. Winners/Holds. Rotation back into risk-on tech.

Cohn observes a rotation where investors are re-evaluating growth numbers for tech and moving into "traditional companies" like Walmart, J&J, Exxon, and Verizon, which are trading near 52-week highs. In an environment of higher interest rates and input costs, capital flees speculative growth for companies with pricing power and tangible cash flows. The "Equal Weight" S&P is outperforming the "Market Cap" weighted index. LONG. Defensive rotation into high-quality legacy assets. If rates drop significantly, capital may flood back into high-beta tech.

Cohn observes a distinct rotation where investors are "reevaluating the growth" of tech companies and moving capital into "traditional companies in America" like Walmart, J&J, Exxon, and Verizon, which are trading near 52-week highs. As high interest rates and input costs persist, investors are seeking safety and realized value over speculative growth. The market isn't exiting equities; it is simply moving to defensive, cash-flow-positive legacy firms. LONG traditional value names as the beneficiaries of this capital rotation. A sudden dovish pivot by the Fed could reignite the risk-on trade in high-growth tech, causing these defensive names to underperform.

Cramer advises investors to "avoid stuff we can't or don't comprehend" and buy companies that "make things and do stuff." These tangible businesses (Consumer Staples, Industrials, Retail) are understandable and less vulnerable to immediate disruption by AI agents compared to complex software companies. Long understandable value and tangible goods. Inflation or consumer spending slowdowns.

JNJ is reportedly looking to *sell* its Orthopedics unit for over $20 billion to Private Equity, rather than the previously planned tax-free spinoff. A sale is often preferred by the market over a spinoff in this environment because it provides immediate liquidity ($20B cash infusion) rather than distributing new equity that investors might sell. This cleans up the balance sheet faster and simplifies the conglomerate structure. LONG on the catalyst of a definitive deal announcement. Regulatory hurdles blocking a sale to PE or valuation coming in under $20B.

Johnson & Johnson (JNJ) is exploring a $20 billion sale of its orthopedic unit. This divestiture would streamline JNJ's focus and provide a massive cash injection for R&D or buybacks. Corporate restructuring of this size often unlocks shareholder value. WATCH. Monitor the deal confirmation and valuation multiple. The sale fails to materialize or regulatory bodies block the transaction.

Investors are fleeing asset-light businesses due to AI disruption fears. Brown identifies "HALO" stocks (Heavy Assets, Low Obsolescence) as the new leadership. An LLM cannot replicate a physical bag of Fritos (Pepsi), refine gasoline (Valero), or pour concrete (Martin Marietta). These companies have "moats of physics" that AI cannot cross. LONG. These sectors (Energy, Industrials, Staples) are seeing massive inflows as "refugees" from the SaaS crash seek safety in non-disruptible cash flows. Some names (like KO) are becoming technically overbought (RSI 85+), suggesting a short-term pullback is likely within a longer uptrend.